This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsLet’s ConnectStock Hub

Example content

CommitmentHeritageInitiativesInnovationPortfolio

Menu

Close

Information on how to access prescribing information and adverse event reporting can be found at the bottom of this page.

Over Two Decades Of Cancer Care ​​​​​​​

Pfizer has a proud heritage within oncology. For over two decades, we have worked tirelessly in our pursuit to develop innovative and accessible treatments for those living with cancer. Today, this is reflected in our extensive portfolio, robust pipeline, and commitment to pursuing breakthroughs that change patients’ lives.1,2 

2000-20102006
  • The United States Food and Drug Administration (FDA) approves Pfizer’s treatment for advanced renal cell carcinoma and gastrointestinal stromal tumours under priority review - the first time the FDA approves a new oncology product for two indications simultaneously3

2010

  • The European Commission approves Pfizer’s treatment for pancreatic neuroendocrine tumours (NETs), representing the first treatment for NETs in 25 years4

2011-2020

2012

  • The European Commission approves another Pfizer treatment for patients with renal cell carcinoma5
  • Conditional marketing authorisation is granted for Pfizer's first-in-class anaplastic lymphoma kinase (ALK)-inhibitor for non-small cell lung cancer (NSCLC), representing a new chapter in biomarker-driven therapy for lung cancer6
​​​​​​​2013
  • The European Commission grants conditional marketing authorisation for Pfizer's chronic myelogenous leukaemia (CML) treatment7
2016
  • ​​​​​​​The European Commission approves Pfizer's first-in-class cyclin-dependent kinase (CDK) 4/6 inhibitor, the first to be approved in Europe. This marks the first treatment for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer in the first-line setting for nearly 10 years8
  • Pfizer's ALK-inhibitor becomes the first FDA- and European Medicines Agency (EMA)- approved treatment for ROS1-positive advanced NSCLC9,10
2017
  • The European Commission approves Pfizer and Merck's treatment for metastatic Merkel cell carcinoma, making it the first approved immunotherapy treatment for this rare and aggressive skin cancer11
  • Also approved is Pfizer's treatment for acute lymphoblastic leukaemia (ALL), offering a treatment option beyond chemotherapy and the first antibody drug conjugate available for patients with this especially hard-to-treat type of leukaemia12
2018
  • The European Commission approves Pfizer's much-needed treatment option for acute myeloid leukaemia (AML), the first therapy to target CD3313​​​​​​​​​​​​​​
2019
  • The European Commission approves Pfizer's treatments for epidermal growth factor receptor (EGFR) mutation-positive NSCLC and germline BRCA-mutated breast cancer14,15
  • Pfizer and Merck's combination treatment in advanced renal cell carcinoma is also approved for first-line use16
  • Conditional marketing authorisation is granted for Pfizer's third-generation ALK-inhibitor - which was specifically developed to penetrate the blood-brain barrier - as a treatment for ALK+ NSCLC. This marks Pfizer's second lung cancer treatment to be approved in 2019 and our third biomarker-driven therapy for lung cancer17
2020
  • ​​​​​​​The European Commission approves Pfizer's hedgehog pathway inhibitor, for the treatment of acute myeloid leukaemia (AML)18
2021 - Present

2021

  • The European commission approves Pfizer and Merck's treatment option for patients with locally advanced or metastatic urothelial carcinoma19


2022

  • The European Commission approves Pfizer's ALK-inhibitor for first-line use in the treatment of ALK+ advanced NSCLC20
Innovation in Oncology 

We are committed to the discovery and development of pioneering therapies that improve the outlook for cancer patients.

Find out more   Loading
Prescribing Information for Great Britain and Northern Ireland:
​​​​​​​

Bavencio®
(avelumab) + axitinib aRCC
Bavencio®
(avelumab) MCC & UC

Besponsa®
(inotuzumab ozogamicin)

Bosulif® (bosutinib monohydrate)

Daurismo®
▼ (glasdegib)

Ibrance® (palbociclib)

Inlyta® (axitinib)

Lorviqua®
(lorlatinib)

Mylotarg®
(gemtuzumab ozogamicin)

Sutent® (sunitinib malate)

Talzenna®
(talazoparib tosylate)

Vizimpro®
(dacomitinib)

Xalkori® (crizotinib)
​​​​​​​
​​​​​​​
References:

1. Pfizer. Products. October 2021. Available at: https://www.pfizer.co.uk/products/prescription-medicines [Last accessed May 2022].

2. Pfizer. Our Therapy Areas: Oncology. November 2021 Available at: https://www.pfizer.co.uk/our-science/our-therapy-areas/oncology [Last accessed May 2022]. 

3. BioSpace. Pfizer Inc.'s Cancer Therapy SUTENT® Receives FDA Approval. January 2006. Available at: https://www.biospace.com/article/releases/pfizer-inc-s-cancer-therapy-sutent-r-receives-fda-approval-/ [Last accessed: May 2022]. 

4. Cision PR Newswire. SUTENT® Receives European Approval for a New Indication in Progressive Pancreatic Neuroendocrine Tumors (NET). December 2010. Available at: SUTENT® Receives European Approval for a New Indication in Progressive Pancreatic Neuroendocrine Tumors (NET) (prnewswire.com) [Last accessed May 2022].
​​​​​​​5. Pfizer press release. Pfizer Receives EU Marketing Authorization for INLYTA® (Axitinib). September 2012. Available at: https://www.pfizer.com/news/press-release/press-release-detail/pfizer_receives_eu_marketing_authorization_for_inlyta_axitinib. [Last accessed: May 2022]. 

6. Pfizer press release. Pfizer’s XALKORI® Receives Conditional Marketing Authorization from the European Commission for the Treatment of Adults with Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer in the EU. October 2012. Available at: https://www.pfizer.com/news/press-release/press-release-detail/pfizer_s_xalkori_receives_conditional_marketing_authorization_from_the_european_commission_for_the_treatment_of_adults_with_previously_treated_alk_positive_advanced_non_small_cell_lung_cancer_in_the_eu [Last accessed May 2022].  

7. Pfizer press release. Pfizer’s BOSULIF® (bosutinib) Receives Conditional Marketing Authorization From The European Commission. March 2013. Available at: https://www.pfizer.com/news/press-release/press-release-detail/pfizer_s_bosulif_bosutinib_receives_conditional_marketing_authorization_from_the_european_commission [Last accessed May 2022].  

8. Pfizer press release. IBRANCE® (palbociclib) Receives Approval in European Union for the Treatment of Women with HR+/HER2- Metastatic Breast Cancer. November 2016. Available at: https://www.pfizer.com/news/press-release/press-release-detail/ibrance_palbociclib_receives_approval_in_european_union_for_the_treatment_of_women_with_hr_her2_metastatic_breast_cancer [Last accessed May 2022].  

9. Pfizer press release. XALKORI® (Crizotinib) Receives Approval In European Union For The Treatment Of Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer. August 2016. Available at: https://www.pfizer.com/news/press-release/press-release-detail/xalkori_crizotinib_receives_approval_in_european_union_for_the_treatment_of_patients_with_ros1_positive_advanced_non_small_cell_lung_cancer [Last accessed May 2022].  

10. Pfizer press release. XALKORI® (crizotinib) Approved by U.S. FDA for the Treatment of Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer. March 2016. Available at: https://www.pfizer.com/news/press-release/press-release-detail/xalkori_crizotinib_approved_by_u_s_fda_for_the_treatment_of_patients_with_ros1_positive_metastatic_non_small_cell_lung_cancer [Last accessed May 2022].  

11. Pfizer press release. European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma. September 2017. Available at: https://www.pfizer.com/news/press-release/press-release-detail/european_commission_approves_bavencio_avelumab_for_metastatic_merkel_cell_carcinoma [Last accessed May 2022].  

12. Pfizer press release. BESPONSA® Approved in the EU for Adult Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia. June 2017. Available at: https://www.pfizer.com/news/press-release/press-release-detail/besponsa_approved_in_the_eu_for_adult_patients_with_relapsed_or_refractory_b_cell_precursor_acute_lymphoblastic_leukemia [Last accessed May 2022].  

13. Pfizer press release. MYLOTARG™ Approved In The EU For The Treatment Of Previously Untreated, De Novo, CD33-positive Acute Myeloid Leukemia In Combination With Chemotherapy. April 2018. Available at: https://www.pfizer.com/news/press-release/press-release-detail/mylotarg_approved_in_the_eu_for_the_treatment_of_previously_untreated_de_novo_cd33_positive_acute_myeloid_leukemia_in_combination_with_chemotherapy [Last accessed May 2022].  

14. Pfizer press release. VIZIMPRO® (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer. April 2019. Available at: https://www.pfizer.com/news/press-release/press-release-detail/vizimpro_dacomitinib_receives_marketing_authorization_in_european_union_eu_for_the_first_line_treatment_of_adult_patients_with_egfr_mutated_non_small_cell_lung_cancer [Last accessed May 2022].  

15. Pfizer press release. European Commission Approves TALZENNA® (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer. June 2019. https://www.pfizer.com/news/press-release/press-release-detail/european_commission_approves_talzenna_talazoparib_for_patients_with_inherited_germline_brca_mutated_locally_advanced_or_metastatic_breast_cancer [Last accessed May 2022].  

16. Pfizer press release. European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma. October 2019. Available at: https://www.pfizer.com/news/press-release/press-release-detail/european_commission_approves_bavencio_avelumab_plus_axitinib_combination_for_first_line_treatment_of_patients_with_advanced_renal_cell_carcinoma [Last accessed May 2022].  

17. Pfizer press release. European Commission Approves LORVIQUA® (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer. May 2019. Available at: https://www.pfizer.com/news/press-release/press-release-detail/european_commission_approves_lorviqua_lorlatinib_for_certain_adult_patients_with_previously_treated_alk_positive_advanced_non_small_cell_lung_cancer [Last accessed May 2022].  

18. Pfizer press release. European Commission Approves DAURISMO™ (glasdegib) for Certain Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). June 2020. Available at: https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-daurismotm-glasdegib-certain [Last accessed May 2022].  

19. Pfizer press release. January 2021. European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma. Available at: https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-bavencior-avelumab-first-line [Last accessed May 2022].  

20. Pfizer press release. European Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung Cancer. January 2022. Available at: https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-lorviquar-lorlatinib-first [Last accessed May 2022].  ​​​​​​​

PP-UNP-GBR-0757. May 2022

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store


Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc


This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ


Copyright © 2021 Pfizer Limited. All rights reserved.


VAT registration number GB201048427

PP-UNP-GBR-0596. April 2022
For UK Healthcare Professionals *

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

​​​​​​I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

​​​​​​​*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.​​​​​​​

​​​​​​​PP-PFE-GBR-3863. November 2021​​​​​​

Yes No
You are now leaving PfizerPro  
​​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

​​​​​​​Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​​​​​​​​
 
You are now leaving PfizerPro  
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021​​​​​​​
 

Add indication message here. It can link a link,
and you can EMBOLDEN text

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?